Quantcast
Last updated on April 18, 2014 at 11:27 EDT

Latest Orexo U.S. Inc. Stories

2013-09-16 12:27:24

In the news release, Zubsolv® Now Available in the U.S. for the Maintenance Treatment of Opioid Dependence, issued 16-Sep-2013 by Orexo U.S. over PR Newswire, we are advised by the company that the phone number in the fifth paragraph and the Orexo U.S., Inc. boilerplate, should read "1-855-ZUBSOLV" rather than "1-888-ZUBSOLV" as originally issued inadvertently. The complete, corrected release follows: Zubsolv® Now Available in the U.S. for the Maintenance Treatment of Opioid Dependence...

2013-09-16 08:28:40

Zubsolv is a new, advanced formulation treatment option for opioid dependent patients that provides higher bioavailability, fast dissolve time, smaller tablet size and a new menthol flavor NEW YORK, Sept. 16, 2013 /PRNewswire/ -- Orexo U.S. announced today that Zubsolv (buprenorphine and naloxone) sublingual tablets (CIII) are commercially available in pharmacies across the United States. In July 2013, Zubsolv received approval from the U.S. Food and Drug Administration (FDA) for the...

2013-07-05 08:22:07

Designed to offer physicians and patients a new choice for opioid dependence, Zubsolv's formulation of buprenorphine and naloxone has higher bioavailability, a fast dissolve time, smaller tablet size and a new flavor NEW YORK, July 5, 2013 /PRNewswire/ -- Orexo U.S., Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Zubsolv (buprenorphine and naloxone) sublingual tablets (CIII). Zubsolv is indicated for the maintenance treatment of...